BioSpace News Archive

SpyBiotech, a biotechnology company with a novel vaccine platform technology that can target infectious diseases, cancer, and chronic diseases, has appointed Keith Dewedoff as Chief Financial Officer.

Belharra Therapeutics, a next-generation chemoproteomics company transforming small molecule drug discovery by illuminating binding pockets on elusive, high-value drug targets across the proteome, today announced a strategic collaboration with Sanofi to advance the discovery of novel small molecule therapeutics for immunological diseases.

Elixir Medical’s DynamX Sirolimus-Eluting Coronary Bioadaptor System Granted FDA Breakthrough Device Designation for the Treatment of Symptomatic Ischemic Heart Disease.

Alvotech and Advanz Pharma announced that the companies have entered into an exclusive partnership agreement regarding the supply and commercialization of Alvotech’s proposed biosimilar to Eylea®.

Nxera Pharma, announces the publication of its Annual Report and its Environment, Social & Governance Report for the year ended 31 December 2023.

Spektar Therapeutics FZCO and Altus Formulation Inc. announced the launch of Spektus Pharma Inc. a new Canadian specialty pharma company developing patent-protected value-added medicines for the growing CNS segment.

Clover Biopharmaceuticals, Ltd. announced positive preliminary immunogenicity and safety data in the older adult & elderly cohort from its Phase Ⅰ trial evaluating SCB-1019 – the company’s bivalent RSV prefusion-stabilized F -Trimer subunit vaccine candidate – which is based on Clover’s Trimer-Tag vaccine technology platform.

AbTherx, Inc., a biotechnology company with innovative technologies that enable and accelerate antibody discovery, announced the opening of its new antibody discovery technologies research center.

NMD Pharma A/S, a clinical-stage biotech company dedicated to developing novel and improved treatments for patients living with severe neuromuscular diseases, today announces that it has received clearance from the US Food and Drug Administration (FDA) for its Investigational New Drug (IND) application to initiate a Phase 2 clinical trial, named SYNAPSE-CMT, of NMD670 in patients living with Charcot-Marie-Tooth (CMT) type 1 and type 2 disease.